Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Ital J Pediatr. 2013 Nov 13;39:72. doi: 10.1186/1824-7288-39-72.
The development of neurological complications due to varicella zoster virus (VZV) reactivation is relatively uncommon, particularly in the case of immunocompetent patients. Only a few cases have been described in the literature, most of which involved adult or elderly patients.
Two days after his pediatrician had diagnosed herpes zoster and prescribed oral acyclovir 400 mg three times a day, a 14-year-old boy was admitted to our hospital because of mild fever, severe headache, slowness, drowsiness and vomiting. A cerebrospinal fluid examination was performed and showed an increased protein concentration (95 mg/dL), normal glucose level (48 mg/dL; blood glucose level, 76 mg/dL) and lymphocytic pleocytosis (1,400 lymphocytes/μL), and VZV DNA was detected by means of polymerase chain reaction (1,250 copies/mL). The results of immunological screening for HIV, lymphocyte subpopulation counts, serum immunoglobulin and complement (C3 and C4) levels, vaccine responsiveness and lymphocytes stimulation tests were unremarkable. Acyclovir was administered intravenously at a dose of 10 mg/kg three times a day and continued for 10 days. The therapy was highly effective and the patient's clinical condition rapidly improved: fever disappeared after two days, and all of the signs and symptoms of neurological involvement after four days. The skin lesions resolved in about one week, and no pain or dysesthesia was ever reported. Given the favourable evolution of the illness, the child was discharged without further therapy after the 10-day treatment. The findings of a magnetic resonance examination immediately after the discontinuation of the antiviral therapy were normal, and a control examination carried out about four weeks later did not find any sign or symptom of disease.
VZV reactivation can also lead to various neurological complications in immunocompetent children. Prompt therapy with acyclovir and the integrity of the immune system are important in conditioning outcome, but other currently unknown factors probably also play a role.
水痘带状疱疹病毒 (VZV) 再激活导致的神经并发症相对较少见,尤其是在免疫功能正常的患者中。文献中仅描述了少数几例,其中大多数涉及成年或老年患者。
一名 14 岁男孩在儿科医生诊断为带状疱疹并开具口服阿昔洛韦 400mg,每日 3 次后两天,因轻度发热、剧烈头痛、动作缓慢、嗜睡和呕吐而入院。进行了脑脊液检查,显示蛋白浓度升高(95mg/dL),血糖水平正常(48mg/dL;血糖水平为 76mg/dL),淋巴细胞增多(1400 个淋巴细胞/μL),并通过聚合酶链反应 (PCR) 检测到 VZV DNA(1250 拷贝/mL)。HIV 免疫筛查、淋巴细胞亚群计数、血清免疫球蛋白和补体(C3 和 C4)水平、疫苗反应性和淋巴细胞刺激试验结果均无异常。阿昔洛韦静脉滴注,剂量为 10mg/kg,每日 3 次,持续 10 天。治疗效果显著,患者的临床状况迅速改善:两天后发热消退,四天后所有神经受累的体征和症状均消失。皮疹在大约一周内消退,从未报告过疼痛或感觉异常。由于病情好转,患儿在 10 天治疗后无需进一步治疗即出院。抗病毒治疗停止后立即进行的磁共振检查结果正常,四周后进行的对照检查未发现任何疾病迹象或症状。
VZV 再激活也可导致免疫功能正常的儿童发生各种神经并发症。及时使用阿昔洛韦进行治疗以及免疫系统的完整性对于预后很重要,但其他目前未知的因素可能也发挥了作用。